Document is current
Any future updates will be listed below
-
Authors
Biglari, Sajjad
Youssefian, Leila
Tabatabaiefar, Mohammad Amin
Saeidian, Amir Hossein
Abtahi‐Naeini, Bahareh
Khorram, Erfan
Sherkat, Roya
Moghaddam, Atefeh Sohanforooshan
Mohaghegh, Fatemeh
Rahimi, Maziyar
Rahimi, Hamid
Babaei, Sharareh
Shahrooei, Mohammad
Mozafari, Nikoo
Zaresharifi, Shirin
Vahidnezhad, Fatemeh
Homayouni, Vida
Tsoi, Lam C.
Gudjonsson, Johann E.
Hakonarson, Hakon
Casanova, Jean-Laurent
Jouanguy, Emmanuelle
Béziat, Vivien
Zhang, Qian
Cobat, Aurélie
Vahidnezhad, Hassan
-
Funding
Funding for this research was provided by:
National Institutes of Health (R01AI143810)
National Institutes of Health (R01AI143810)
National Institutes of Health (R01AI143810)
LEO Fondet (LF-OC-22-000965)
- License Information
-
More Information
Article History
Received: 13 March 2024
Accepted: 16 March 2025
First Online: 28 March 2025
Declarations
:
: This study is in partial fulfillment of S.B. 's PhD thesis, and it was approved by the Ethics Committee of the Isfahan University of Medical Sciences (IR.MUI.MED.REC.1401.255).
: Jean-Laurent Casanova serves on the scientific advisory boards of ADMA Biologics Inc., Kymera Therapeutics, and Elixiron Immunotherapeutics. Johann E. Gudjonsson has served as an advisor for Almirall, Eli Lilly, Sanofi, Novartis, BMS, Janssen, Boehringer Ingelheim, and received research grants from Almirall, Prometheus Biosciences, Janssen, Eli Lilly, Boehringer Ingelheim, Galderma. Hakon Hakonarson and Children’s Hospital of Philadelphia are equity holders in Nobias Therapeutics, developing MEK inhibitor therapy for complex lymphatic anomalies.The authors declare no competing interests.Other authors declare no conflict of interest.
